New drug FS1502 shows promise in early trial for Hard-to-Treat HER2 cancers
NCT ID NCT03944499
First seen Nov 01, 2025 · Last updated May 19, 2026 · Updated 25 times
Summary
This early-phase trial tested a new drug called FS1502 in 161 adults with advanced HER2-positive solid tumors or breast cancer that had stopped responding to standard treatments. The main goals were to check the drug's safety, find the best dose, and see if it shrinks tumors. Results will help decide if larger studies are warranted.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, Beijing Municipality, 100021, China
-
Henan Cancer Hospital
Zhengzhou, Henan, China
-
Jilin Cancer Hospital
Jilin, Changchun, China
-
Meizhou People's Hospital
Meizhou, Guangdong, China
-
Run Run Shaw Hospital Affiliated to Medical College of Zhejiang University
Hangzhou, Zhejiang, 310016, China
-
Shandong Cancer Hospital
Jinan, Shandong, China
-
Shenzhen Hospital, Cancer Hospital, Chinese Academy of Medical Sciences
Shenzhen, Guangdong, 518000, China
-
Sun Yat-sen University Cancer Prevention Center
Guangzhou, Guangdong, China
-
The First Affiliated Hospital of Bengbu Medical College
Bengbu, Anhui, China
-
The Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, 050011, China
-
Tianjin Cancer Hospital
Tianjin, Tianjin Municipality, China
-
Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
Conditions
Explore the condition pages connected to this study.